Algorae Pharmaceuticals Limited
LVCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | -500.8% | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | -514.8% | – |
| EPS | -0 | -0 | -0 | -0.001 |
| % Growth | 75% | 0% | 55.6% | – |
| EPS Diluted | -0 | -0 | -0 | -0.001 |
| Weighted Avg Shares Out | 1,518 | 1,632 | 1,587 | 1,640 |
| Weighted Avg Shares Out Dil | 1,687 | 1,687 | 1,686 | 1,640 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | -$1 |
| % Margin | – | – | -343.7% | – |